Antidepressants Normalize the Default Mode Network in Patients With Dysthymia
Jonathan Posner, David J Hellerstein, Inbal Gat, Anna E. Mechling, Kristin Klahr, Zhishun Wang, Patrick J. Mcgrath, Jonathan W. Stewart, Bradley S. Peterson
JAMA Psychiatry February 6, 2013 DOI: 10.1001/jamapsychiatry.2013.455 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Placebo-controlled Double-blind Peer reviewed |
|---|---|
| Sample size | 41 |
| Population | Subjects with dysthymic disorder and healthy control participants aged 18 to 53 years |
| Intervention | Duloxetine |
| Duration | 10-week intervention |
| Topics | Default mode network Depression |
| Keywords | Resting State FMRI Duloxetine Placebo Functional connectivity Magnetic resonance imaging Antidepressant Mood Hippocampus Pathology |
| Citations | 275 |
| Key findings | At baseline, coherence of neural activity within the brain's default mode network was greater in persons with dysthymic disorder compared with healthy controls; after 10 weeks, treatment with duloxetine, but not placebo, normalized DMN connectivity. |
Abstract
Importance: The default mode network (DMN) is a collection of brain regions that reliably deactivate during goal-directed behaviors and is more active during a baseline, or so-called resting, condition. Coherence of neural activity, or functional connectivity, within the brain's DMN is increased in major depressive disorder relative to healthy control (HC) subjects; however, whether similar abnormalities are present in persons with dysthymic disorder (DD) is unknown. Moreover, the effect of antidepressant medications on DMN connectivity in patients with DD is also unknown.
Objective: To use resting-state functional-connectivity magnetic resonance imaging (MRI) to study (1) the functional connectivity of the DMN in subjects with DD vs HC participants and (2) the effects of antidepressant therapy on DMN connectivity.
Design: After collecting baseline MRI scans from subjects with DD and HC participants, we enrolled the participants with DD into a 10-week prospective, double-blind, placebo-controlled trial of duloxetine and collected MRI scans again at the conclusion of the study. Enrollment occurred between 2007 and 2011.
Setting: University research institute.
Participants: Volunteer sample of 41 subjects with DD and 25 HC participants aged 18 to 53 years. Control subjects were group matched to patients with DD by age and sex. MAIN OUTCOME MEASURES: We used resting-state functional-connectivity MRI to measure the functional connectivity of the brain's DMN in persons with DD compared with HC subjects, and we examined the effects of treatment with duloxetine vs placebo on DMN connectivity.
Results: Of the 41 subjects with DD, 32 completed the clinical trial and MRI scans, along with the 25 HC participants. At baseline, we found that the coherence of neural activity within the brain's DMN was greater in persons with DD compared with HC subjects. Following a 10-week clinical trial, we found that treatment with duloxetine, but not placebo, normalized DMN connectivity.
Conclusions: AND RELEVANCE: The baseline imaging findings are consistent with those found in patients with major depressive disorder and suggest that increased connectivity within the DMN may be important in the pathophysiology of both acute and chronic manifestations of depressive illness. The normalization of DMN connectivity following antidepressant treatment suggests an important causal pathway through which antidepressants may reduce depression.
Comparable studies
Other randomized controlled trials on default mode network, most cited first.
Citations in the library
Cited by 20
- Evidence that Subanesthetic Doses of Ketamine Cause Sustained Disruptions of NMDA and AMPA-Mediated Frontoparietal Connectivity in Humans Journal of Neuroscience August 19, 2015
- The anterior cingulate cortex as a key locus of ketamine’s antidepressant action Neuroscience & Biobehavioral Reviews May 10, 2021
- MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens Neuropsychopharmacology November 20, 2020
- Modulation of the functional connectome in major depressive disorder by ketamine therapy. Psychological Medicine October 1, 2022
- Functional connectivity between the amygdala and subgenual cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment‐resistant depression Neuropsychopharmacology Reports February 21, 2021
and 15 more in the library